# Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

> **NCT00060307** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00060307
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060307, "Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00060307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*